Skip to main content
OpenTrials
Completed

NCT Number: NCT03356184

Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients

This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring. The primary variables for the analysis of heart rate (HR) and respiratory rate (RR) are each of the overall mean roots mean square difference (RMSD). Results of the investigational device and reference device compared with the patient monitor is evaluated to see if there are equivalent. Motion and bed exit accuracy will be evaluated by comparing with the manual observation.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Virginia Commonwealth University School of Medicine

Richmond, Virginia, 23298-0102, United States

About this study

Tests (periods 1 and 2), one of the contact-free devices will be used to monitor the HR and RR, while being compared with the Patient Monitor. The RHEA investigational device and reference device will be used to monitor the same subject at different times, as the sensors of the two devices are placed at a similar location of the bed. HR and RR will be recorded for all three devices.

The primary hypotheses for HR, are as follows:

Adults HO: μ = 3.25 vs. HA: μ < 3.25

The primary hypotheses for RR, are as follows:

Adults HO: μ = 2.25 vs. HA: μ < 2.25 where μ represents the population mean HR or RR. If the upper bound of the confidence interval is less than the hypothesized value, the corresponding null hypothesis will be rejected. Comparison of the performance of the two contract-free devices will be performed on the recorded results via statistical analysis. The hypothesis here is that the two devices have equivalent performance. The third test will assess the ability of the RHEA device to accurately detect motion in or exit from the bed, as compared to the manual observation. Motion and no motion accuracy will each be calculated along with their respective two-sided 95% confidence intervals.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, 18 years old and above.
  • Provide written informed consent.
  • Weight ranging from 20 to 150 kg inclusive.
  • Are located in a non-ICU hospital setting.
  • Agree to not eat during the testing period.
  • Agree to keep still.

Exclusion criteria

  • Are connected to a device which may interfere with the device monitoring in this study.
  • Are receiving any bedside care which may be incompatible with the study procedures.
  • Sleep apnea.
  • Pregnant or breast feeding.
  • A likely need to receive or undergo a procedure during the testing period.
  • Cannot accept a nasal cannula, or have a monitor lead placed on the chest.
  • A significant medical condition in the judgement of the investigator, which may compromise the study testing procedures.
  • Are wearing pacemaker or defibrillator.

Treatment and study plan

The Rhea Vital Sign Vigilance Device Group

Device

The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

The Earlysense System Device Group

Device

The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.

Primary outcomes

  1. Root-mean-square Deviation of Heart Rate

    Time frame: 30 days

    Calculate the root-mean-square deviation (RMSD) of the heart rate using 20 pairs of valid and synchronously recorded heart rate of investigational device and patient monitor.

  2. Root-mean-square Deviation of Respiratory Rate

    Time frame: 30 days

    Calculate the root-mean-square deviation (RMSD) of the respiratory rate using 20 pairs of valid and synchronously recorded respiratory rate of investigational device and patient monitor.

Secondary outcomes

  1. Heart Rate t Test Comparison result between the Investigational Device and the Reference Device

    Time frame: 30 days

    Record 20 valid heart rate displayed in the reference device and patient monitor at the same time every one minute.

    Calculate the t test results for heart rate for the reference device and the investigational device.

  2. Respiratory Rate t Test Comparison result between the Investigational Device and the Reference Device

    Time frame: 30 days

    Record 20 valid respiratory rate displayed in the reference device and patient monitor at the same time every one minute. Calculate the t test results for respiratory rate for the reference device and the investigational device.

  3. Motion Notification Accuracy(%)

    Time frame: 30 days

    Record the time for each instructed movements from manual observation and time for movements notification shown in the investigational device. Calculate the times matched between these two to get the accuracy.

  4. Bed Exit Notification Accuracy(%)

    Time frame: 30 days

    Record the time for each instructed bed exit from manual observation and time for bed exit notification shown in the investigational device. Calculate the times matched between these two to get the accuracy.

Sponsors and collaborators

Lead sponsor

Darma Inc.

Industry

Collaborators

  • Virginia Commonwealth University

Registry information

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Nov 29, 2017
Registry last updated
Apr 16, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.